Data are provided as n, unless indicated otherwise. SCIT: subcutaneous
immunotherapy; SD: standard deviation; AR: Allergic rhinitis; AC:
Allergic conjunctivities; IBS: irritable bowel syndrome;
V0: patients at the first visit; V1:
patients at 1-year follow up; COVID-19: coronavirus disease
2019.
1AIT was given by increased dose every 1-2 weeks until
the maximum tolerated dose of the individual was reached.
2 The maximum tolerated dose of the patients was given
subcutaneously every 4-6 weeks for 2 years.
* P value of < 0.05 was considered as
statistically significant.